What the FDA labels say about taking them together
Binimetinib and encorafenib
Binimetinib's FDA label of March 20, 2025 names encorafenib in its warnings and precautions section, and encorafenib's label names binimetinib too. The encorafenib label: “Hepatotoxicity: Monitor liver function tests before and during treatment with BRAFTOVI and binimetinib and as clinically indicated.”
Check it at the source: the binimetinib FDA label on DailyMed (effective March 20, 2025, Array BioPharma Inc.); the encorafenib FDA label on DailyMed (effective February 26, 2026, Array BioPharma Inc.).
What does the binimetinib label say about encorafenib?
Binimetinib label, warnings and precautionsNew Primary Malignancies, Cutaneous and Non-cutaneous: Can occur when MEKTOVI is used in combination with encorafenib.
Source: FDA drug label (MEKTOVI), Array BioPharma Inc., effective March 20, 2025 (SPL set 6c3408ac-d401-4925-8a03-26591afbc240), via openFDA; the full label on DailyMed
What does the encorafenib label say about binimetinib?
Encorafenib label, warnings and precautionsHepatotoxicity: Monitor liver function tests before and during treatment with BRAFTOVI and binimetinib and as clinically indicated.
Source: FDA drug label (BRAFTOVI), Array BioPharma Inc., effective February 26, 2026 (SPL set 235dfc38-0f0b-4037-b501-7a9f4294740c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Binimetinib | Encorafenib | |
|---|---|---|
| Labeled for | Lung cancer | Colorectal cancer, Lung cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once